Australia Becomes the First Country to Prescribe Psychedelics to Treat Depression and PTSD
Australia has become the first country to prescribe MDMA to treat PTSD and psilocybin to combat treatment-resistant depression.
compass pathways
The Largest Phase 3 Trial on Psilocybin for Depression Has Kicked Off
The largest Phase 3 clinical trial investigating the efficacy and tolerability of psilocybin for treatment-resistant depression (TRD) has finally begun.
Single Dose of Psilocybin Yields Long-Term Depression Remission in Over 50% of Cancer Patients
A single 25mg dose of psilocybin paired with psychological support has resulted in 57% of patients.
‘Right To Try Laws’ and Legal Access to Psilocybin Therapy with Dr. Jonathan Fields
Petitioning the DEA to respect the ‘Right to Try Laws’ which empower terminally ill patients to legally access psilocybin therapy.
Compass Pathways Phase 2 Psilocybin Results far from Spectacular
Psilocybin showed rapid antidepressant effects for most patients, but only 1 in 5 participants showed significant improvement at 12 weeks
Math Over Myth: Compass and Revive Release Phase 3 Updates but Stocks Drop
Math over Myth is your weekly source for psychedelic stock updates, including Compass Pathways and Revive Therapeutics
Math Over Myth: Spotlight on Psychedelic Stocks ATAI & COMPASS
If you want to invest in psychedelic stocks, ignore the hype and look at the technicals. We take a deep dive on atai Life Sciences & COMPASS Pathways
Psychedelic Stocks: ARK Invest and the Reverse Midas Touch
Cathie Wood is buying up stocks from the most dubious actors in the psychedelic sector. Given ARK Invest’s subpar performance, is that a good thing?
Compass Pathways Sued for Stealing Trade Secrets
Compass Pathways faces a legal challenge from Terran Biosciences over the potential theft of intellectual property
Three Phase 3 Clinical Trials that Could Legalize Psychedelics
The road to psychedelic legalization has many paths. These 3 clinical trials have the best chances to legalize psychedelics for therapy
End of content
End of content